Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06008275 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jun 2026 → Jun 2027
See other at-risk trials from Baylor Research Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 2026 to Jun 2027 Show 4 more changesShow less
    • Study completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 39 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site contact updated
  2. Re-verified, no change to tracked fieldsv5
  3. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Jun 2025 to Jun 2026
    • Study completion date: Dec 2025 to Dec 2026
    • Start date changed from estimate of Aug 2024 to Sep 16, 2024
    • Site details revised
  4. Start date: Nov 2023 to Aug 2024v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.
Trial Details
NCT Number NCT06008275
Lead Sponsor Baylor Research Institute
Conditions
(from sponsor)		 Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Related terms Breast Neoplasms, Triple Negative Breast Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov